A task force details its findings of the risks associated with using convalescent plasma using failure mode and effects analysis
Shilpa Jindani
Advertisement
Shilpa Jindani is medical director, Family Medicine, Thousand Oaks, CA.
Articles by Shilpa Jindani
Advertisement
Latest Updated Articles
- A Systematic Evaluation of Risks and Mitigation Strategies for Convalescent Plasma Therapy for COVID-19
Published: February 3rd 2021 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
5
